Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solrikitug in adults with eosinophilic esophagitis
2024-510849-34-00Phase 2Authorised
- Sponsor
- NI-One
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Solrikitug with Placebo (2 arms). Primary endpoints: Histologic remission at Week 24, Change in dysphagia symptom score at Week 24 and 3 more. Planned start Feb 2025; status: authorised.
02
Drugs
solrikitug
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2024-510849-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510849-34-00.